Its new pancreatic cancer drug is likely to gain regulatory approval and begin commercialization in 2021, SynCore Biotechnology Co (杏國) said at the BioTaiwan Exhibition in Taipei yesterday.
The late-stage pancreatic cancer drug, SB05, has passed phase I and II clinical trials in the US, and has received approval to conduct a phase III trial, the Taipei-based company said.
SB05 has also gained orphan drug designation from US and EU regulators, which is expected to speed up the review process, it said.
“SB05 has shown favorable results in its phase II trial, demonstrating improved overall survival [OS] and progression-free survival [PFS] readings compared with patients given gemcitabine, the standard treatment for pancreatic cancer,” SynCore general manager Su Muh-hwan (蘇慕寰) said.
While SB05 would be introduced to the market as a pancreatic cancer treatment, it has completed phase II studies against triple-negative breast cancer and neoadjuvant HER2(-) breast cancer, as well as liver metastasis, Su said.
Despite the tremendous market potential for breast cancer treatments, there are already a lot of companies in the field, and the disease has many variations, he said.
Only about 15 percent of breast cancer patients worldwide have triple-negative breast cancer, but in Asia the figure is about 10 percent due to genetic factors, he said.
Other potential applications include lung, prostate and neoadjuvant pancreatic cancer, he said.
SB05’s effectiveness in clinical trials is due to the firm’s proprietary EndoTAG technology platform, he said.
EndoTAG is a delivery mechanism that can “envelope”’ a variety of drugs, he said, adding that the company is open to working with other drug developers.
However, production facilities at the company’s parent, Sinphar Group (杏輝藥業集團), cannot mass produce EndoTAG drugs as they have not been certified by European and US regulators, Su said.
“We currently rely on a German contract manufacturer to make small batches of SB05 for clinical trials, but our Taiwanese facility should be ready in time for the drug’s commercialization,” Su said.
In the pipeline are SB01, a head and neck cancer treatment; SB02, a gastric cancer treatment; and SB04, an eye-drop for age-related macular degeneration, he said.
Su said that biotech companies manufacturing lower-priced generic drugs and health supplements, such as Sinphar Group, have the most to gain from the government’s “new southbound policy,” but the high cost of oncology drugs and other medicines might be out of reach of most the region’s population.
SynCore is the development arm of Sinphar Group. It oversees clinical trials and seeks regulatory approval for drugs producted by the parent’s preclinical research department.
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group